A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
In this study, a medicine called cevostamab will be tested to see if it is safe and how well it works for people with a type of cancer called multiple myeloma. It will be given through a needle in the vein, either alone or with other medicines. The study will include people whose cancer has come back or did not respond to previous treatment.
In this study, a medicine called cevostamab will be tested to see if it is safe and how well it works for people with a type of cancer called multiple myeloma. It will be given through a needle in the vein, either alone or with other medicines. The study will include people whose cancer has come back or did not respond to previous treatment.
*Third Opinion AI Generated Synopsis
Trial Summary
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: